A Phase 2, Single-Arm, Open-Label Study Using Itacitinib as Pre-Modulation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Receiving CAR-T-Cell Therapy
Latest Information Update: 18 Mar 2025
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Itacitinib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 13 Mar 2025 Planned End Date changed from 1 Apr 2026 to 1 Jun 2026.
- 13 Mar 2025 Planned primary completion date changed from 1 Apr 2025 to 1 Jun 2025.
- 10 Dec 2024 Planned End Date changed from 1 Dec 2025 to 1 Apr 2026.